Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.413 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.2437 | 0.4856 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.406 | 0.9788 | 0.9706 |
Giardia lamblia | Hypothetical protein | 0.2437 | 0.4856 | 0.5 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.2437 | 0.4856 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.413 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.413 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.406 | 0.9788 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.2368 | 0.4645 | 0.4645 |
Schistosoma mansoni | 6-phosphofructokinase | 0.413 | 1 | 1 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.2437 | 0.4856 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.406 | 0.9788 | 0.9788 |
Brugia malayi | Voltage-gated calcium channel, L-type, alpha subunit. C. elegans egl-19 ortholog | 0.0839 | 0 | 0.5 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.406 | 0.9788 | 0.9706 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.413 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.2437 | 0.4856 | 0.5 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.413 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.413 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.406 | 0.9788 | 0.9706 |
Onchocerca volvulus | 0.413 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | > 30 uM | Inhibition of TDP2 (unknown origin) using 4-nitrophenyl phenylphosphonate as substrate after 60 mins | ChEMBL. | 23859074 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.